Targeting invadopodia to block breast cancer metastasis

Oncotarget

Volumn 2, Issue 7, 2011, Pages 562-568

  Eckert, Mark A ^a,b   Yang, Jing ^a  

^a Department of Pharmacology ^*  (United States)

^b The Molecular Pathology Graduate Program   (United States)

Author keywords

Breast cancer; Invadopodia; Invasion; Metastasis; MMP; MT1 MMP; PDGFR; Podosomes; SFK; SrC; Twist1

Indexed keywords

ABELSON KINASE; BOSUTINIB; COLONY STIMULATING FACTOR; DASATINIB; DX 2400; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GELATINASE A; GELATINASE B; IMATINIB; KS 2391; KX 2391; LAPATINIB; METALLOPROTEINASE; MONOCLONAL ANTIBODY; NEUTROPHIL COLLAGENASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; STEM CELL FACTOR; SUNITINIB; TRANSCRIPTION FACTOR TWIST; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; ACTIN; NUCLEAR PROTEIN; PEPTIDE HYDROLASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; TWIST1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CELL ORGANELLE; CLINICAL TRIAL (TOPIC); DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL DISEASE; HUMAN; INVADOPODIA; METASTASIS INHIBITION; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CANCER INVASION; CELL SURFACE; DRUG ANTAGONISM; DRUG EFFECT; EXTRACELLULAR MATRIX; FEMALE; GENETICS; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ACTINS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURFACE EXTENSIONS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FEMALE; HUMANS; METALLOPROTEASES; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PEPTIDE HYDROLASES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TWIST TRANSCRIPTION FACTOR;

EID: 84862833208     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.301     Document Type: Article

References (54)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA: A Cancer Journal for Clinicians. 2004; 54: 8-29.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007; 18: 581-92.
3. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nature Rev Cancer. 2003; 3: 453-8.
4. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119: 1420-8.
5. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995; 154: 8-20.
6. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nature Rev Cancer. 2007; 7: 415-28.
7. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117: 927-39.
8. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007; 18: 215-25.
9. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nature Rev Drug Discovery. 2006; 5: 821-34.
10. Hopkins AL, Groom CR. The druggable genome. Nature Rev Drug Discovery. 2002; 1: 727-30.
11. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. Oncotarget; 1: 651-661.
12. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008; 68: 3645-54.
13. Tarone G, Cirillo D, Giancotti FG, Comoglio PM, Marchisio PC. Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. Exp Cell Res. 1985; 159: 141-57.
14. Chen WT. Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J Exp Zool. 1989; 251: 167-85.
15. Yamaguchi H, Oikawa T. Membrane lipids in invadopodia and podosomes: Key structures for cancer invasion and metastasis. Oncotarget. 2010; 1: 320-328.
16. Linder S. Invadosomes at a glance. J Cell Sci. 2009; 122: 3009-13.
17. Linder S. The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol. 2007; 17: 107-17.
18. Seals DF, Azucena EF, Pass I, Tesfay L, Gordon R, Woodrow M, Resau JH, Courtneidge SA. The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell. 2005; 7: 155-65.
19. Ayala I, Baldassarre M, Giacchetti G, Caldieri G, Tetè S, Luini A, Buccione R. Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J Cell Sci. 2008; 121: 369-78.
20. Chen WT. Proteases associated with invadopodia, and their role in degradation of extracellular matrix. Enzyme Prot. 1996; 49: 59-71.
21. Buschman MD, Bromann PA, Cejudo-Martin P, Wen F, Pass I, Courtneidge SA. The novel adaptor protein Tks4 (SH3PXD2B) is required for functional podosome formation. Mol Bio Cell. 2009; 20: 1302-11.
22. Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, Yang J. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 2011; 19: 372-86.
23. Bowden ET, Onikoyi E, Slack R, Myoui A, Yoneda T, Yamada KM, Mueller SC. Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp Cell Res. 2006; 312: 1240-53.
24. Yu J, Ustach C, Kim H-RC. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol. 2003; 36: 49-59.
25. Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003; 130: 4769-84.
26. Li X, Kumar A, Zhang F, Lee C, Li Y, Tang Z, Arjuna P. VEGF-independent angiogenic pathways induced by PDGF-C. Oncotarget. 2010; 1: 309-314.
27. Kypta RM, Goldberg Y, Ulug ET, Courtneidge SA. Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell. 1990; 62: 481-92.
28. Yang Y, Yuzawa S, Schlessinger J. Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. PNAS. 2008; 105: 7681-6.
29. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grünert S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest. 2006; 116: 1561-70.
30. Quintavalle M, Elia L, Condorelli G, Courtneidge SA. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol. 2010; 189: 13-22.
31. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer. 2002; 38 Suppl 5: S19-27.
32. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee B-N, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancerexpressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol. 2008; 19: 1713-9.
33. Mundhenke C, Strauss A, Schem C. Significance of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Breast Cancer. Breast Care. 2009; 4: 373-378.
34. Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opinion on Investigational Drugs. 2009; 18: 821-34.
35. Mader CC, Oser M, Magalhaes MAO, Bravo-Cordero J, Condeelis JS, Koleske AJ, Gil-Henn H. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res. 2011; 71: 1730-41.
36. Steger GG, Abrahámová J, Bacanu F, Brincat S, Brize A, Cesas A, Cufer T, Dank M, Duchnowska R, Eniu A, Jassem J, Kahán Z, Matos E, Padrik P, Plāte S, Pokker H, et al. Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener Klinische Wochenschrift. 2010; 122: 368-79.
37. Lurje G, Lenz H-J. EGFR signaling and drug discovery. Oncology. 2009; 77: 400-10.
38. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 2008; 25: 843-54.
39. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD. A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis. 2010; 28: 137-55.
40. Morgan L, Nicholson RI, Hiscox S. SRC as a therapeutic target in breast cancer. Endocrine, Metabolic & Immune Disorders Drug Targets. 2008; 8: 273-8.
41. Azam M, Nardi V, Shakespeare WC, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. PNAS. 2006; 103: 9244-9.
42. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 2010; 16: 3526-32.
43. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nature Rev Clin Oncol. 2009; 6: 587-95.
44. Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J, Duffy MJ. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol. 2011: mdq757-.
45. Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer. 2010; 11: 238-42.
46. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 2008; 15: 422-32.
47. Wolf K, Friedl P. Mapping proteolytic cancer cellextracellular matrix interfaces. Clin Exp Metastasis. 2009; 26: 289-98.
48. Tatin F, Varon C, Génot E, Moreau V. A signalling cascade involving PKC, Src and Cdc42 regulates podosome assembly in cultured endothelial cells in response to phorbol ester. J Cell Sci. 2006; 119: 769-81.
49. Rowe RG, Li X-Y, Hu Y, Saunders TL, Virtanen I, Garcia de Herreros A, Becker K-F, Ingvarsen S, Engelholm LH, Bommer GT, Fearon ER, Weiss SJ. Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. J Cell Biol. 2009; 184: 399-408.
50. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, Muijen GN van. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol. 2000; 191: 245-56.
51. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011; 278: 16-27.
52. Balbín M, Fueyo A, Tester AM, Pendás AM, Pitiot AS, Astudillo A, Overall CM, Shapiro SD, López-Otín C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003; 35: 252-7.
53. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, Chang E, Tao Q, Vanhove M, Lejeune A, Gool R van, Sexton DJ, Kuang G, Rank D, Hogan S, Pazmany C, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009; 69: 1517-26.
54. Lauer-Fields J, Brew K, Whitehead JK, Li S, Hammer RP, Fields GB. Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors. J Am Chem Soc. 2007; 129: 10408-17.